 |
|
|
| |
Safety, Tolerability, and Pharmacokinetics of BMS-986263/ND-L02-s0201, A Novel Targeted Lipid Nanoparticle
Delivering HSP47 siRNA, in Healthy Participants: A Randomised, Placebo-Controlled, Double-Blind, Phase 1 Study
|
| |
| |
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
Benjamin Soule, Giridhar S. Tirucherai, Uma Kavita, Sudeep Kundu, Rose Christian
Bristol-Myers Squibb, Princeton, NJ, USA
|
| |
|
|
|
|
|
